Vanguard Group Inc Arca Biopharma, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Arca Biopharma, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 453,598 shares of ABIO stock, worth $1.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

453,598

Previous 453,598 -0.0%

Holding current value

$1.51 Million

Previous $771,000 3.5%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.7 - $2.05 $5,207 - $6,279	3,063 Added 0.68%	453,598 $771,000
Q3 2023 Nov 14, 2023	SELL	$2.01 - $2.07 $22,266 - $22,931	-11,078 Reduced 2.4%	450,535 $905,000
Q2 2023 Aug 14, 2023	SELL	$1.94 - $2.11 $10,848 - $11,799	-5,592 Reduced 1.2%	461,613 $937,000
Q1 2023 May 15, 2023	BUY	$1.99 - $2.55 $15,522 - $19,890	7,800 Added 1.7%	467,205 $929,000
Q4 2022 Feb 10, 2023	BUY	$1.86 - $2.44 $437 - $573	235 Added 0.05%	459,405 $1.09 Million

Q3 2022 Nov 14, 2022	SELL	$2.13 - $2.51 $2,232 - $2,630	-1,048 Reduced 0.23%	459,170 $946,000
Q2 2022 Aug 12, 2022	BUY	$2.2 - $2.53 $1,443 - $1,659	656 Added 0.14%	460,218 $1.15 Million
Q1 2022 May 13, 2022	BUY	$1.77 - $2.49 $94,303 - $132,664	53,279 Added 13.11%	459,562 $1.06 Million
Q4 2021 Feb 14, 2022	SELL	$2.15 - $2.97 $23,596 - $32,595	-10,975 Reduced 2.63%	406,283 $874,000
Q3 2021 Nov 12, 2021	BUY	$2.77 - $3.74 $51,940 - $70,128	18,751 Added 4.71%	417,258 $1.24 Million
Q2 2021 Aug 13, 2021	BUY	$3.06 - $3.9 $1.22 Million - $1.55 Million	398,507 New	398,507 $1.39 Million

Others Institutions Holding ABIO

# of Institutions

Shares Held

7.23M

Call Options Held

54.7K

Put Options Held

View Full List

About ARCA biopharma, Inc.

Ticker ABIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,410,100
Market Cap $48M
Description
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydr...

More about ABIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Arca Biopharma, Inc. Transaction History